Therapy News and Research

RSS

Preliminary results from CINJ's Celebrex and Lipitor Phase II combination trial on prostrate cancer

Research from The Cancer Institute of New Jersey (CINJ) on the FDA-approved drugs Celebrex and Lipitor -- used respectively for arthritis pain and lowering cholesterol -- shows that these drugs are well tolerated in the treatment of recurrent prostate cancer.

1 Feb 2012

Dana-Farber receives MLSC grant to expand cancer imaging research

The Massachusetts Life Sciences Center has awarded Dana-Farber Cancer Institute a $10 million grant to support the expansion of its pioneering cancer imaging research program.

1 Feb 2012

Crizotinib can treat ROS1-driven tumors

A report from investigators at the Massachusetts General Hospital (MGH) Cancer Center has defined the role of a recently identified gene abnormality in a deadly form of lung cancer. Tumors driven by rearrangements in the ROS1 gene represent 1 to 2 percent of non-small-cell lung cancers (NSCLC), the leading cause of cancer death in the U.S.

1 Feb 2012

Scientists identify TDO enzyme as new target for cancer therapy

Scientists from the Ludwig Institute for Cancer Research (LICR) in Brussels identified a new target for cancer therapy, an enzyme which prevents the immune system from recognizing and destroying certain types of tumors.

1 Feb 2012

Vertex receives FDA approval for Kalydeco to treat rare form of CF

The U.S. Food and Drug Administration today approved Kalydeco (ivacaftor) for the treatment of a rare form of cystic fibrosis (CF) in patients ages 6 years and older who have the specific G551D mutation in the Cystic Fibrosis Transmembrane Regulator (CFTR) gene.

1 Feb 2012

Biogen Idec 2011 total revenues increase 7% to $5.0 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced its full year and fourth quarter 2011 results.

1 Feb 2012

Breast cancer survivors use at-home method to prep their breasts for reconstruction

NewYork-Presbyterian Hospital/Columbia University Medical Center is the first hospital in the New York metro area to offer breast cancer survivors an at-home method for tissue expansion in preparation for breast reconstruction surgery. Patients use a remote control to gradually create a space within their chest wall for a breast implant.

31 Jan 2012

ESC welcomes 'intriguing' study on heart failure

The European Society of Cardiology (ESC) welcomes an "intriguing" study, published today in the Journal of the American College of Cardiology, featuring a completely novel approach for improving endothelial function in heart failure.

31 Jan 2012

CDC models show scaling up ART for HIV treatment can save money over time

During a webinar Thursday hosted by the Health Global Access Project, AVAC, and amfAR, John Blandford, chief of CDC's Division of Global HIV/AIDS Health Economics, Systems and Integration Branch, presented findings showing "that scaling up antiretroviral therapy (ART) for HIV/AIDS treatment and prevention in the developing world not only saves lives, but saves money too," the Center for Global Health Policy's "Science Speaks" blog reports.

31 Jan 2012

HSP40/70 linked to hepatitis C infection

Researchers from UCLA's Jonsson Comprehensive Cancer Center have identified a cell-permeable peptide that inhibits a hepatitis C virus protein and blocks viral replication, which can lead to liver cancer and cirrhosis.

31 Jan 2012

Study pinpoints genetic factors behind increased ALL risk in Hispanic children

Hispanic children are more likely than those from other racial and ethnic backgrounds to be diagnosed with acute lymphoblastic leukemia (ALL) and are more likely to die of their disease. Work led by St. Jude Children's Research Hospital scientists has pinpointed genetic factors behind the grim statistics.

31 Jan 2012

AT&T donates US$29,000 to Camp Quality

AT&T Inc. continues to support Australian charities and has donated US$29,000 to Camp Quality, a charity that supports children living with cancer and their families in Australia.

31 Jan 2012

Ariz. hospitals fighting losses in political shift and in court; Ga. seeking second cancer center

A look at hospital news around the country also includes reports on a Mayo collaboration in Minnesota on immigrant health, plans for a proton cancer therapy center in South Florida and efforts by Tufts Medical Center to get a level one trauma center.

31 Jan 2012

UMC to offer ditto device for pediatric patients

Diversionary Therapy Technologies is pleased to announce one of the first U.S. sales of its groundbreaking ditto device, which is clinically proven to lower anxiety and treatment times while improving pediatric patient outcomes. UMC Health System, based in Lubbock, Texas, has purchased and will be offering this revolutionary aid to children at the hospital.

31 Jan 2012

Juventas' JVS-100 Phase I heart failure trial meets primary safety endpoint

Juventas Therapeutics is a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease. The Company's lead product, JVS-100, encodes Stromal cell-Derived Factor 1 (SDF-1) which has been shown to repair damaged tissue through recruitment of circulating stem cells to the site of injury, prevention of ongoing cell death and restoration of blood flow.

31 Jan 2012

Researchers decipher genetic material of 48 pediatric glioblastomas

Glioblastomas grow extremely aggressively into healthy brain tissue and, moreover, are highly resistant to radiation therapy and chemotherapy. Therefore, they are regarded as the most malignant type of brain tumor. Currently available treatment methods are frequently not very effective against this type of cancer. Glioblastoma can affect people of all ages, but is less common in children than in adults.

31 Jan 2012

End alternative medicine degrees say scientists

A group of more than 400 doctors, medical researchers and scientists are urging universities to close down alternative medicine degrees.

30 Jan 2012

FDA approves Medtronic DF4 High-Voltage Connector System for ICDs and CRT-Ds

Medtronic, Inc. today announced the U.S. Food and Drug Administration (FDA) approval and launch of the DF4 High-Voltage Connector System, a right ventricular lead and connector used with implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds) to detect and accurately treat potentially life-threatening heart rhythms.

From Medtronic 30 Jan 2012

Fat grafting may reduce radiation-induced complications in breast implants

For breast cancer patients who have undergone radiation therapy, a new technique consisting of fat injection followed by implant placement may provide a much-needed alternative for breast reconstruction, reports a study in the February issue of Plastic and Reconstructive Surgery®, the official medical journal of the American Society of Plastic Surgeons (ASPS).

30 Jan 2012

Newly discovered molecular pathway may explain how AML develops

Researchers at UC Santa Barbara have discovered a molecular pathway that may explain how a particularly deadly form of cancer develops. The discovery may lead to new cancer therapies that reprogram cells instead of killing them. The findings are published in a recent paper in the Journal of Biological Chemistry.

30 Jan 2012